{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-233939","form_type":"8-K","ticker":null,"cik":"0001850266","company_name":"Akili, Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.760138+00:00","generated_at":"2026-06-10T19:24:00.796544+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Akili shifts to non-prescription model, cuts workforce 40%, extends cash runway to 2H 2025","bullets":["Workforce reduced ~40%; field sales and market access teams eliminated, representing ~2/3 of cuts. Severance cost estimated $2.3–2.8M.","EndeavorOTC generated 125,971 first-time downloads, 4,170 active subscribers, $81.88 ARPU in first three months.","2023 non-GAAP total opex guidance $55–60M; 2024 non-GAAP opex $42–47M.","Cash, cash equivalents, and short-term investments expected to fund operations into 2H 2025.","Non-prescription model expected to achieve 60–70% gross margins by late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-233939","json":"https://secwatch.observer/filing/0001193125-23-233939.json","markdown":"https://secwatch.observer/filing/0001193125-23-233939.md","text":"https://secwatch.observer/filing/0001193125-23-233939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850266/000119312523233939/0001193125-23-233939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850266/000119312523233939/d554445d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:24:00.796544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"468e90232d2e80f056380466bc6b9a521e8be03d","claim":"Akili, Inc. announced a restructuring with charges of approximately $2.3 – $2.8 million affecting the Company (approximately 40%).","evidence_excerpt":"of 2023. Affected employees will be offered severance and other benefits, and the Company estimates that these severance and termination-related costs will be approximately $2.3 – $2.8 million and expects to record these charges in the third quarter of 2023. The Company also expects that payments of most of these costs will be made in 2023. As a result of","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850266/000119312523233939/0001193125-23-233939-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.3 – $2.8 million"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"approximately 40%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}